BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...on contributions from six prior investors including MPM Capital, its founding investor.The funds will carry Werewolf Therapeutics Inc....
...UPMC Enterprises and DC Investment Partners, as well as MPM.TARGETSIL-2 – Interleukin-2IL-12 – Interleukin-12 Paul Bonanos Werewolf Therapeutics Werewolf Therapeutics Inc....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...to the newly created role of chief development officer from SVP, corporate strategy and health policy.Werewolf Therapeutics Inc....
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

...handed off the reins to Lara Sullivan in December. Longwood also backed the launch of Werewolf Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...on contributions from six prior investors including MPM Capital, its founding investor.The funds will carry Werewolf Therapeutics Inc....
...UPMC Enterprises and DC Investment Partners, as well as MPM.TARGETSIL-2 – Interleukin-2IL-12 – Interleukin-12 Paul Bonanos Werewolf Therapeutics Werewolf Therapeutics Inc....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...to the newly created role of chief development officer from SVP, corporate strategy and health policy.Werewolf Therapeutics Inc....
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

...handed off the reins to Lara Sullivan in December. Longwood also backed the launch of Werewolf Therapeutics Inc....
Items per page:
1 - 3 of 3